The U.S. Food and Drug Administration has approved Siemens Healthcare’s VERSANT(TM) 440 Molecular System for marketing for use with the VERSANT HCV RNA 3.0 assay for management of HCV-infected patients undergoing antiviral therapy.

The VERSANT 440 Molecular System represents the next generation in automated viral load testing, providing laboratories with greater throughput and less hands-on time, maximizing productivity to meet the evolving needs of the clinical laboratory. We are pleased to offer clinical laboratories leading-edge solutions in molecular diagnostics that support cost-effective and timely screening and treatment of infectious disease.

Siemens Healthcare Diagnostics Division is the leading clinical diagnostics provider in the world. The VERSANT 440 Molecular System is a branched DNA (bDNA) system designed for flexible walk-away automation. Its single room technology and consolidated footprint allow the system the flexibility to fit anywhere in the clinical laboratory. The VERSANT 440 System streamlines workflow by integrating bar code data entry, automated reagent processing, signal amplification detection, and a Laboratory Information System interface for downloading patient work lists and results.